The Cigna (CI) Q3 2026 Earnings Call: Q&A Summary

Q: Lisa Gill with JPMorgan asked about the progression of the Signature model rollout in 2027 and how to bridge to the low single digit guidance for Evernorth.

A: Brian Evanko, President and CEO, explained that the Signature model aims to tackle high-cost branded drugs and is currently in Phase 2 build and contracting, with broad adoption expected in 2028. Ann Dennison, CFO, noted that Specialty and Care will grow within its 8% to 12% range while Pharmacy Benefit Services will be down single digits due to industry-wide rebate pressures and lower GLP-1 weight-loss coverage.

Q: Kevin Fischbeck with Bank of America asked about the $0.60 drag from the exchange exit and how much might be recaptured in 2028, and whether 2028 will see more normal specialty launches.

A: Ann Dennison stated that exiting the exchange market represents an all-in headwind of about $200 million and runoff/stranded costs would be addressed in 2028. Brian Evanko added that 2027 is a slower year for specialty biosimilars and generics, but 2028 through 2030 will see several new biosimilars coming to market.

Q: A.J. Rice with UBS asked if there is any short-term pressure from deploying the Signature model to the fully insured book and how the company complies with recent PBM regulations.

A: Brian Evanko answered that the Signature rollout for the fully insured book on January 1 is not a 2027 headwind because pricing is handled through standard underwriting. He also stated that Cigna will comply with the Department of Labor PBM transparency rule and that the Signature model is designed to comply with evolving regulations.

Q: Justin Lake with Wolfe Research asked to rank order the three Evernorth headwinds and how to think about investment gains in 2026 as a headwind for Healthcare next year.

A: Brian Evanko and Ann Dennison stated they will provide detailed guidance in the fourth quarter, noted that the two PBS headwinds are relatively equal, and Ann Dennison added that 2026 investment gains should not be characterized as a headwind for 2027.

Q: Scott Fidel with Goldman Sachs asked about the run rate savings expected to accrue into the 2027 outlook from Lead to One and Accelerate to One, along with potential onetime costs.

A: Ann Dennison explained that the $3 billion in gross run rate savings by 2030 will come from automation, modernization, and talent effectiveness, with execution costs reflected in strategic optimization program disclosures mostly concentrated on severance.

Q: Jason Cassorla with Guggenheim Securities asked how script growth declines are being addressed for 2027 given the strong selling season.

A: Brian Evanko responded that script counts are no longer a great indicator of financial health due to specialty drug proliferation. He noted that retention is tracking in high 90s and new business is tracking to at least 2 million new PBS customers in 2027.

Q: Charles Rhyee with TD Cowen asked about the impact of 340B program changes on specialty care and services and whether Part B infusion OPPS cuts impact Shields.

A: Brian Evanko stated that Accredo's 340B contract pharmacy exposure is very small and any downward pressure is modest and easily overcome. Regarding Shields, he noted that investment income does not consolidate into Cigna's results, but regulatory complexity increases hospital demand for Shields' services.

Q: Elizabeth Anderson with Evercore ISI asked how stop-loss is performing relative to the middle market and current expectations for January 1 pricing.

A: Ann Dennison replied that year-to-date frequency trends and high-cost claimants have been stable and consistent with expectations, and pricing captures the objective to recapture margin over 2026 and 2027.

Q: Dean Dallas with Leerink Partners asked if state-level activity regarding vertical integration changes how Cigna thinks about Evernorth's operating model.

A: Brian Evanko stated that Cigna does not pursue integration for its own sake, but sees tremendous benefits in affordability, patient satisfaction, and health outcomes through connected data and coordinated care.

Q: Erin Wright with Morgan Stanley asked if distribution and medical benefit opportunities in specialty are drivers for 2027 or longer term.

A: Brian Evanko explained that distribution expansion and medical benefit specialty penetration are longer-term builders rather than outsized 2027 contributors, with distribution targeting $45 billion by 2030 and medical benefit biosimilars scaling later in the decade.